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Background: To enhance the dissemination of the ARIA document (Allergic rhinitis (AR) and its impact on asthma) in
Mexico, a Working Group composed of 35 specialists of 8 professional medical societies developed a transculturized
ARIA México 2014 guideline. The ARIA guidelines use the GRADE system, which builds recommendations and
suggestions around clinical questions (CQ).
Methods: As part of the dissemination strategy and to detect the physicians’ view and knowledge-gaps concerning
the treatment of AR an online survey was sent out to members of participating societies containing the CQ of ARIA
México. Replies were analyzed per specialty against the ARIA México 2014 experts’ recommendations/suggestions;
differences between specialties were analyzed with Pearson’s Chi-squares.
Results: 807 surveys were returned, 657 completed (81%). We analyze replies from 158 alergists, 188 ENTs, 64
pulmonologists, 220 pediatricians and 177 GPs/family doctors. More than half of the surveyed physicians of all
specialties would give an allergen reduced diet to pregnant/lactating women and avoid pets at home, which is against
ARIA experts’ suggestions. ARIA experts suggest intranasal antihistamines can be part of the AR treatment: 46-63% of
the ENTs, pulmonologists and pediatricians disagree; and experts prefer oral H1-antihistamines over leukotriene
receptor antagonists (LTRA) for the treatment of AR: 52-36% of the pulmonologists, pediatricians and GPs prefer LTRAs.
Concerning glucocorticosteroids (GCS): GPs are more reluctant to use intranasal GCS (p < 0.001) and 47% prefers oral
H1-antihistamines. As for the treatment of recalcitrant AR ARIA experts suggest the use of oral, but not intramuscular,
GCS: a quarter of pulmonologists, pediatricians and GPs considers they should not be used. Contrarily, 40% of ENTs
favors intramuscular GCS. In patients with AR and comorbid asthma several physicians of all specialties –except
pulmonologists- erroneously considers antihistamines, intranasal GCS and LTRAs useful for the treatment of asthma,
while first-line recommended asthma treatment is inhaled GCS.
Conclusion: On certain issues in the treatment of AR the physicians’ opinion diverges from the recommendations/
suggestions of ARIA experts. Moreover, physicians’ opinions depend on their specialty. As such, an online survey can
help to detect knowledge-gaps and guide the development of more focused and specialty-specific postgraduate
learning tools.
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The international guidelines on allergic rhinitis (AR) and
its impact on asthma (ARIA) have been developed in col-
laboration with the World Health Organization since 2001.
They were updated in 2008 and 2010. Several other well-
designed guidelines on the diagnosis and treatment of al-
lergic rhinitis exist, for example the practice parameters on
allergic rhinitis developed by a joint effort of the American
College and the Academy of Allergy, Asthma and Immun-
ology [1,2]. However, the use of the GRADE system
(Grading of Recommendations Assessment, Development
and Evaluation [3]), the straight-forward presentation built
around clinical questions and the emphasis on the close
link between AR and allergic asthma are some unique fea-
tures of the ARIA guidelines. Although some experts have
made their critical comments on some parts of ARIA [4,5],
the impact of the ARIA documents on the international
medical community has been broad, changing the classifi-
cation of AR, improving the diagnosis of co-morbid
asthma and enhancing the more comprehensive treatment
of AR. Even so and although ARIA 2010 has been trans-
lated into Spanish, its content is hardly known to physi-
cians outside the circle of experts in Mexico. Mexican
specialists felt a formal transculturization of the guideline
would enhance its acceptability among primary and spe-
cialized health care workers. As such, ARIA México 2014
was created, see Figure 1, and published.(paper version [6]
and online www.guiasdealergia.com) Part of the process of
clinical guideline making is the formulation of clinical
questions. We have used these clinical questions of ARIA
México 2014 to obtain the opinion concerning the treat-
ment of AR from physicians of different specialties in-
volved in the management of patients with AR. To that
end an online survey with the clinical questions was sent
out to the membership of the eight medical societies in-
volved in the creation of ARIA México 2014. The results
of this survey shall be presented in this document and its
online supplementary files against the background of the
ARIA recommendations and suggestions.
Methods
During the transculturization process of the international
ARIA 2010 guideline the clinical questions of ARIA 2010
[7] were translated and adjusted to the Mexican reality by
the Mexican Working Group on ARIA, a group of 35 na-
tional experts in allergy, otorhinolaryngology, pulmonol-
ogy, pediatrics and family medicine, to create the ARIA
México 2014 clinical questions. [See Additional file 1:
‘Questionnaire as sent out via Survey Monkey of clinical
questions of ARIA México 2014’ (Word document)]. The
46 questions in total are grouped into eight areas, ranging
from prevention, to treatment of allergic rhinitis without
and with asthma, immunotherapy and alternative medicine
–see below under results-. While the Working Groupanalyzed how to best formulate answers to the clinical
questions based on evidence, patient preference, cost and
safety issues using the GRADE system (Grading of Recom-
mendations Assessment, Development and Evaluation) [3],
closely adhering to the clinical evidence from the original
ARIA 2010 publication, we decided to also consult the
membership of professional medical societies on these is-
sues. Thus, the translated and adjusted clinical questions of
ARIA Mexico 2014 [6] were sent out to the membership
of societies of specialists in the above mentioned areas by
means of an online survey instrument (Surveymonkey®).
Members of the Association of Family Physicians preferred
to complete the survey on paper. As for some specialties
there exist two societies, the total number of participating
societies adds up to eight.
The replies to the clinical questions are presented per
specialty and statistically significant differences between
specialties are calculated with Pearson’s chi-square tests, if
necessary with Yates’ correction, using a two-tailed test.
We considered p < 0.05 to be significant. Only in those
cases where statistically significant differences between
groups could be detected, this shall be discussed.
Results and their discussion
A total of 807 surveys were filled in, of which 81% (657
surveys) were completed. We analyze here the replies of
158 allergists, 188 ENTs, 64 pulmonologists, 220 pediatri-
cians and 177 GPs/family doctors. The complete file with
graphs of all replies per question and per specialty can be
found in the Additional file 2: ‘Replies to ARIA México
2014 questions per specialty’ (Powerpoint file).
Primary prevention of IgE mediated respiratory allergies
In the section of primary prevention physicians agree on
the importance of exclusive breastfeeding as one of the
suggestions to reduce the development of allergies in
the newborn. Recent allergy-prevention guidelines of the
European Academy of Allergy, Asthma and Immunology
recommend exclusive breastfeeding during the first four
months to all newborns [8], but in ARIA it is still only at
the level of a suggestion. The pediatricians are stronger
in favor of this recommendation (p < 0.001), see Table 1.
Avoidance of tobacco smoke and occupational allergens
are recommendations embraced by over 95% of our
physicians.
However, among the opinions of the physicians on issues
concerning primary prevention two main discrepancies
can be detected between the suggestions/recommenda-
tions of the experts and the opinion of the members at
large. In line with ARIA 2010, ARIA México 2014 experts
suggest not to prescribe any allergen avoidance diet to
pregnant or breast-feeding women. However, this is rec-
ommended by 35-50% of the physicians of all specialties,
including 38.8% of the pediatricians, see Figure 2. Also, the
Figure 1 Flowdiagram of the development of ARIA México 2014.
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out animal dander allergy can have pets in their homes,
but avoidance of animal dander and pets is unnecessarily
prescribed by most of the surveyed physicians, including
54% of the pediatricians.
Secondary prevention of IgE mediated respiratory
allergies
In the section on secondary prevention surveyed mem-
bers of the participating societies of specialists agree
with the ARIA México 2014 expert suggestions to avoid
contact with the specific allergen in sensitized and aller-
gic patients. ARIA México 2014 suggests the use of nasal
washes as part of the treatment of allergic rhinitis. A
quarter of the surveyed and 32% of the GPs does not yet
agree with this strategy, which is a low-cost intervention,
that has been shown to reduce some of the nasalsymptoms and as such European ENT specialists also
suggest its use [9].
Treatment of allergic rhinitis without asthma,
I: antihistamines
In the first block on the treatment of allergic rhinitis,
some interesting findings can be presented. Both ARIA
2010 and ARIA México 2014 recommend non-sedating
oral H1-antihistamines, with no hepatic metabolism as
first line treatment for allergic rhinitis. Almost a fifth of
the pulmonologists and GPs do not consider antihista-
mines for the treatment of allergic rhinitis and 11% of
the GPs still prefers first generation antihistamines over
the newer, less sedating ones, see Table 2.
On the other hand there is a considerable group of
physicians that attributes preventive effects to antihista-
mines, they only possess in a highly selected group of
Figure 2 Physicians' opinion on ARIA question 2 concerning the prescription of a maternal diet during pregnancy and lactation to prevent
the development of allergies.
Table 1 Percentage of the surveyed physicians answering in line with the ARIA México 2014 recommendations/suggestions
on primary prevention (ARIA Guideline, Block 1)
Clinical questions Block 1: Primary prevention ARIA México
2014#
% of physicians with the ‘correct’ answer##
Allergists ENTs Pulm Peds GPs
1. To prevent allergy: Should exclusive breastfeeding be given? Sug: yes 67 64 63 90*** 76
2. To prevent development of allergy in children: Should allergen
avoidance diet be used in pregnant or breast-feeding women?
Sug: No 49 35 40 39 50
3. To reduce the risk of developing allergy/wheezing/asthma in children:
should children-pregnant women avoid environmental tobacco smoke?
Rec: yes 98 98 98 99 96
4. To reduce the risk of developing allergy to house dust mite and asthma:
¿Should infants and preschool children avoid exposure to house dust mite?
Sug: yes 76 71 61 73 74
5. Concerning the risk to develop allergy and asthma: Can infants and
pre-school children without animal dander allergy have pets in their homes?
Sug: yes 50 42 61 47 32***
6. Should specific measures reducing occupational agent exposure be
used to decrease the risk of sensitization and subsequent development
of occupational rhinitis and asthma?
Rec: yes 95 96 97 96 90
# ARIA México recommendation (R) or suggestion (S).
## = % of physicians per specialty answering as suggested/recommended by ARIA México 2014 [6].
*** = p < 0.001 statistically significant difference with the opinion of the allergists.
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Figure 3 Physicians' opinion on ARIA question 18 concerning the use of leukotriene receptor antagonists versus new generation oral
H1-antihistamines in the treatment of allergic rhinitis.
Table 2 Percentage of the surveyed physicians answering in line with the ARIA México 2014 recommendations/
suggestions on the 1st part of the treatment of allergic rhinitis: antihistamines (ARIA Guideline, Block 3)




% of physicians with the ‘correct’ answer##
Allergists ENTs Pulm Peds GPs
12. Should oral H1-antiH be used for the treatment of AR? R: 2ndge-neration 93 93 81 90 83
13. Should new-generation oral H1-antiH versus old-generation
oral H1-antiH be used for the treatment of AR?
R: 2ndge-neration 96 96 94 92 89
14. Should oral H1-antiH be used in preschool children with
other allergic diseases for the prevention of wheezing or asthma?
Sug: no 69 46*** 68 60 41***
15. Should intranasal H1-antiH be used for treatment of AR? Sug: yes 65 54 37*** 45 76
16. Should newer oral H1-antiH versus intranasal H1-antiH be
used for treatment of AR?
S:new, oral anti-H1s 77 69 74*** 59 57***
17. Should oral leukotriene receptor antagonists be used
for treatment of AR?
Sug: yes 66 70 82* 70 62
18. Should oral leukotriene receptor antagonists versus oral
H1-antiH be used for treatment of AR?.
S:new, oral anti-H1s 85 81 59*** 48*** 64***
H1-antiH = H1 antihistamines, # ARIA México recommendation (R) or suggestion (S).
## = % of physicians per specialty answering as suggested/recommended by ARIA México 2014 [6].
* = p < 0.05 and *** = p < 0.001 statistically significant difference with the opinion of the allergists.
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[10]. In total still over a third of all respondents would
treat children with allergic rhinitis with antihistamines in
the hope they can prevent the development of asthma
with this intervention, as formerly was advocated but not
sustained with more recent research. More than half of
the pulmonologists and pediatricians do not like intranasal
antihistamines. Finally, over half of the pulmonologists
and pediatricians prefer leukotriene receptor antagonists
(LTRAs) over oral antihistamines for the treatment of al-
lergic rhinitis, see Figure 3. A metanalysis showed that
monotherapy with an antihistamine or LTRAs has low to
moderate efficacy in the treatment of seasonal AR, but
both are less effective than intranasal GCS [11]. LTRAs
might be useful, especially for the nighttime symptoms of
AR [12], but not allergic conjunctivitis [13]. Recently, a
combination of both, antihistamine plus LTRAs has been
showing promising results for patients with AR [14].
Treatment of allergic rhinitis without asthma,
II: glucocorticosteroids
For patients with more severe disease, intranasal gluco-
corticosteroids are recommended by the experts of both
ARIA teams. Over the whole board physicians agree
with this vision. However, quite a large fraction of GPs is
reluctant to use topical corticosteroids, see Table 3.
As for systemic glucocorticosteroids in patients not well
controlled on other medication, ARIA experts suggest the
use of short cycles of oral glucocorticosteroids, but warn
for the use of intramuscular long-acting glucocorticoster-
oids. A quarter of the pulmonologists, pediatricians and
GPs does not favor the use of any systemic glucocorticos-
teroids. On the contrary, 40% of the ENTs considers intra-
muscular glucocorticosteroids can be used in the treatment
of allergic rhinitis.Table 3 Percentage of the surveyed physicians answering in l
suggestions on the 2nd part of the treatment of allergic rhini




19. Should intranasal glucocorticosteroids be used
for treatment of AR?
R: Yes (adu
S: Yes (chil
20. Should intranasal gluco-corticosteroids (GCS) versus
oral H1-antiH be used in patients with AR?.
S: inGCS
21. Should intranasal GCS versus intranasal H1-antiH be
used in patients with AR?
R: inGCS
22. Should intranasal GCS versus oral leukotriene receptor
antagonists be used for treatment of AR?
R: inGCS
23. Should oral GCS be used for treatment of AR in
patients not responding to other therapy?
S: yes, shor
24. Should intramuscular GCS be used for treatment of AR? R: no
# ARIA México recommendation (R) or suggestion (S).
## = % of physicians per specialty answering as suggested/recommended by ARIA M
* = p < 0.05, ** = p < 0.01 and *** = p < 0.001 statistically significant difference with tTreatment of allergic rhinitis without asthma,
III: other medication
Although the ARIA experts suggest intranasal chromones
as an alternative option in the treatment of allergic rhin-
itis, the majority of physicians of all specialties surveyed is
not in in favor of this management modality. When asked
to opt between intranasal chromones or intranasal antihis-
tamines, the latter is their favorite choice for most, al-
though a third of the pulmonologists, pediatricians and
GPs does favor chromones. The recommended adminis-
tration frequency for intranasal chromones is qid, which is
difficult to accomplish. Moreover, lately intranasal chro-
mones have been scarce on the Mexican market; these
two issues might have influenced the Mexican physicians’
opinion on this drug negatively.
General physicians are tempted to use topical decon-
gestants for the treatment of AR much more often than
all other specialties (76% vs. 41-49%, p < 0.001 for all).
On the other hand a higher percentage of ENTs have a
favorable opinion about the use of oral decongestants
for the treatment of AR compared to all other specialties
(67% vs. 33-50%, p < 0.005 for all). An important finding
is that when asked to compare the use of an oral
H1-antihistamine alone or in combination with a decon-
gestant, the majority of all physicians opts for the com-
bination, including a 66% of the allergists. This is in
contrast with the ARIA experts’ suggestion to use topical
decongestants only in short cycles and to refrain from
using oral decongestants on a regular base. However, the
replies to the clinical questions on decongestants are
somewhat difficult to interpret, as the questions did not
state any specific time interval. Certainly these are no
maintenance drugs for the treatment of allergic rhinitis,
but can eventually be used in short cycles in patients with
a high degree of nasal obstruction.ine with the ARIA México 2014 recommendations/
tis: glucocorticosteroids (ARIA Guideline, Block 4)
ico % of physicians with the ‘correct’ answer##
Allergists ENTs Pulm Peds GPs
lt) 97 97 96 91 83***
d)
73 61 88 76 53***
92 88 92 90 66***
90 82 84 75*** 70***
t 87 87 73* 72** 72**
88 60*** 88 95 88
éxico 2014 [6].
he opinion of the allergists.
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ment option can be the ocular administration of antihista-
mines or chromones. More than half of the GPs and over
a third of the pulmonologists and pediatricians do not
consider these options, suggested by the ARIA experts.
Treatment of allergic rhinitis and concomitant asthma
An adequate treatment of the nasal symptoms, e.g. with
new generation oral H1 antihistamines or intranasal GCS
is mandatory for the control of comorbid asthma, however
ARIA experts consider there is very little or no place for
oral H1-antihistamines in the direct management of
asthma. This is in line with the recommendations of the
Global Initiative on Asthma (GINA) guidelines, update
2014 [15] and most surveyed pulmonologists go along
with this. However, less than half of the surveyed ENTs
and GPs agree and also 42% of the allergists and pediatri-
cians state antihistamines can be used for the treatment of
asthma in patients with allergic rhinitis and asthma, see
Figure 4. Also, a combination of antihistamines and oralFigure 4 Physicians' opinion on ARIA question 42 concerning the use o
rhinitis and asthma, for the treatment of asthma.decongestant is considered useful for the treatment of
asthma by half of the ENTs and GPs. Similarly, more than
half of the physicians would use intranasal glucocorticos-
teroids for the treatment of asthma for patients with
AR-asthma, with the exception of the pulmonologists.
LTRAs are an option for the treatment of asthma in co-
morbid AR patients in the eyes of more than 90% of the
surveyed, except for the GPs. Some care should be taken
on this issue, as GINA and ARIA experts clearly state that
an inhaled corticosteroid is the first option in maintenance
monotherapy for asthma, LTRAs are a second line option.
Finally, monoclonal antibodies against IgE (omalizumab®)
are indicated in severe asthmatic patients, but four out of
ten ENTs, pediatricians and GPs do not consider this
treatment as an option yet. (p < 0.01 compared with pul-
monologists and allergists). For the time being omalizu-
mab is a suggested treatment, as its cost and mode of
administration make it still amendable for improvement.
Also, it has till now been approved in Mexico for children
12 years and up.f new generation oral H1-antihistamines in patients with allergic
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The here presented survey forms part of the ARIA México
project, which final goal is improving the recognition, diag-
nosis and treatment of allergic rhinitis, especially in the
context of co-morbid asthma. Consulting the membership
of the colleges of allergists, otorhinolaryngologists (ENTs),
pulmonologists, pediatricians and family physicians had aTable 4 Recommendations and Suggestions of ARIA México 2
Recommendations* or Suggestions* to be reinf
Allergist S: Indicate exclusive breastfeeding to prevent allerg
S: Oral LTRAs can be used for treatment of AR
ENT S: Indicate exclusive breastfeeding to prevent allerg
S: The use of intranasal GCS is suggested over the u
R: Intramuscular GCS are not recommended for trea
S: In patients with AR and asthma Anti-IgE monoclo
Pulmonologist S: Indicate exclusive breastfeeding to prevent allerg
S:Infants and preschool children should avoid expo
S: Nasal washes can be indicated as an integral par
S: The use of oral H1-antihistamines is suggested o
S: Intranasal antihistamines are suggested over IN-c
S: Intraocular H1-antiH be used for the treatment o
Pediatrician S: The use of oral H1-antihistamines is suggested o
R: The use of intranasal GCS is recommended over
S: Intranasal antihistamines are suggested over IN-c
S: Intraocular H1-antiH be used for the treatment o
S: In patients with AR and asthma Anti-IgE monoclo
GP S: Nasal washes can be indicated as an integral par
S: The use of oral H1-antihistamines is suggested o
S: Oral LTRAs can be used for treatment of AR
S: The use of oral H1-antihistamines is suggested o
S: The use of intranasal GCS is suggested over the u
R: The use of intranasal GCS is recommended over
S: Intranasal antihistamines are suggested over IN-c
S: Intraocular H1-antiH be used for the treatment o
Anti-IgE monoclonal antibodies can be used for th
All S:No allergen-avoidance diets should be used in pr
S: infants and pre-school children without animal d
S: Oral H1-antihistamines should NOT be used in pr
wheezing or asthma
S: intranasal H1-antihistamines can be used for the
S: intranasal chromones can be used in AR treatme
S: Intranasal decongestant can be used for AR treat
S: We suggest oral H1 antihistamines as regular AR
S: Intraocular chromones can be used for the treatm
S: In patients with AR and asthma: Oral H1 antihista
NOT be used for the treatment of asthma.
* For recommendations: > 20% opted for the non-recommended alternative.
** For suggestions: > 30% opted for the non-suggested alternative.triple objective: firstly, asking the membership of distinct
medical societies for their opinion on the clinical questions
got them more involved in the ARIA México project; sec-
ondly, this enabled the Working Group to detect know-
ledge gaps and areas susceptible for improvement
according to the different specialties. This opens the possi-




se of oral H1-antihistamines in AR treatment
tment of AR?
nal antibodies can be used for the treatment of asthma.
y
sure to HDM to reduce the risk of developing HDM allergy/asthma.
t of the treatment of AR. (69%)
ver the use of oral LTRAs in AR treatment.
hromones in AR treatment
f ocular symptoms in patients with ARC
ver the use of oral LTRAs in AR treatment.
the use of oral LTRAs in AR treatment.
hromones in AR treatment
f ocular symptoms in patients with ARC
nal antibodies can be used for the treatment of asthma.
t of the treatment of AR.
ver the use of intranasal H1 antihistamines
ver the use of oral LTRAs in AR treatment.
se of oral H1-antihistamines in AR treatment
the use of intranasal H1-antihistamines and LTRAs in AR treatment
hromones in AR treatment
f ocular symptoms in patients with ARCS: In patients with AR and asthma
e treatment of asthma.
egnant or breastfeeding women
ander allergy can have pets in their homes
eschool children with other allergic diseases for the prevention of
treatment of AR
nt
ment, but only in a short cycle.
treatment, not combined with decongestant
ent of ocular Sx in patients with ARC
mines with or without decongestants, intranasal GCS or LTRAs should
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percentage of members with an opinion different from that
of the ARIA experts, while in other cases only some spe-
cialties diverged from the experts, see Table 4.
Table 4 can give a lead as to on which areas continuous
medical education should be focused per specialty. The
third aim of the survey was to create expectations among
medical societies’ members with respect to the ARIA
Mexico 2014 guideline, serving as such as a pre-launch
tool for the final guideline document. This was obvious
during conferences given on this subject at national con-
gresses at which assistants commented they attended the
talk to auto-evaluate their replies to the survey.
Conclusions
Using a low-cost online survey with the clinical questions
of a national guideline on the treatment of allergic rhinitis
and its impact on asthma (ARIA México 2014 [6]) enabled
us to obtain a better view on the physician’s opinion on the
prevention and treatment of AR and to detected specialty-
specific knowledge-gaps. The management decisions of the
medical community are not always in line with the ARIA
expert recommendations and suggestions and there is a dif-
ference between specialties in the weak spots, sensitive to
improvement. Moreover, the survey might have served as a
tool in drawing the attention of the medical community to
allergy and the prevention, diagnosis and treatment of aller-
gic rhinitis, as well as to the launch of the national guideline
ARIA México 2014.
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